Back to top
more

Amarin (AMRN)

(Real Time Quote from BATS)

$0.61 USD

0.61
232,926

+0.01 (0.88%)

Updated Nov 5, 2024 11:43 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Amarin (AMRN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss

by Zacks Equity Research

Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.

Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall

by Zacks Equity Research

Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Ekta Bagri headshot

Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More

by Ekta Bagri

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.

Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are likely to have driven first-quarter sales.

Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.

GSK Gears Up to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.

Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Protagonist (PTGX) Up on Positive Results From FRONTIER Study

by Zacks Equity Research

Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.

Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase

by Zacks Equity Research

Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.

Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.

Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales

by Zacks Equity Research

Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.

Amicus (FOLD) Q4 Earnings Miss, Galafold Sales Beat Estimates

by Zacks Equity Research

Amicus (FOLD) posts a wider-than-expected fourth-quarter loss but strong sales of its solely marketed drug Galafold drive the top line.

Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues beat estimates.

Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil

by Zacks Equity Research

Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.

Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.

FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.

Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down

by Zacks Equity Research

Novavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with earnings and revenues both missing the Zacks Consensus Estimate. Stock plunges 26.1% in response to the news.

Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales

by Zacks Equity Research

Perrigo (PRGO) reports mixed fourth-quarter 2022 results. While the company beats the mark on earnings, it misses sales estimates.

Acadia (ACAD) Q4 Earnings Miss, Nuplazid Sales Boost Revenues

by Zacks Equity Research

Acadia Pharmaceuticals (ACAD) reports mixed results for the fourth quarter of 2022, recording wider-than-expected loss per share and better-than-expected revenue figures owing to the sales of Nuplazid.

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Karuna Therapeutics (KRTX) reports encouraging fourth-quarter 2022 results. The company beats estimates for earnings and sales.